Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pediatric Rheumatology Year in Review, 2021: Basic Science

Elizabeth Sloan, MD  |  December 9, 2021

These offspring exposed to either maternal infection or IL-6 had improved survival when infected with Salmonella, but they were more susceptible to developing non-infectious intestinal inflammation. The authors concluded that an infectious-driven host imprinting occurs in the offspring during maternal infection. Further, this imprinting may provide protective immunity from future infections, but at the expense of an increased predisposition for non-infectious inflammatory disorders.

Immune Dysregulation & Autoinflammation

Borrowing a term from her colleagues in clinical immunology, Dr. Vogel displayed several recent papers on Hot New Defects, specifically focused on recent discoveries in immune dysregulation and autoinflammation. She selected one paper to discuss in detail, Taft et al., which describes four patients from three families with deficiency in TANK binding kinase 1 (TBK1).7 TBK1 is considered important in innate immunity and is involved in proper responses to viruses, so a deficiency in TBK1 would be expected to cause defective immune response to viral infection, she explained.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, the authors presented cases of absolute or functional defects in TBK1, which resulted in significant autoinflammation and underlined the role of TBK1 downstream of tumor necrosis factor (TNF) signaling. Anti-TNF therapy seems to be an effective therapy for these patients.

She explained that these “experiments of nature” continue to unveil the complexities of the immune system, and this specific study has taught us more about cell-death regulation pathways downstream of TNF signaling.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

ADA2 Genetic Variants

Dr. Vogel ended with a study by Jee et al. in which investigators looked at functional studies of adenosine deaminase 2 (ADA2) activity from samples with known ADA2 genetic variants.8 The researchers included population variants, as well as pathogenic variants associated with the autoinflammatory disease known as deficiency of adenosine deaminase 2 (DADA2).

Their results demonstrated a full spectrum of variant impact on ADA2 activity. They also showed a correlation between plasma ADA2 activity and the measured in vitro activity. These findings suggest that functional assays may prove beneficial in future interpretations of ADA2 variants and allow for further understanding of DADA2.

In Sum

This year-in-review session highlighted many exciting discoveries in the basic and translational sciences related to pediatric rheumatology. Dr. Vogel discussed advances in genetics, autoinflammation and immune dysregulation as well as several studies that enhance our understanding of the pathogenesis of lupus, arthritis and other rheumatic diseases.

These breakthroughs may pave the way for improved subgrouping of diseases, new diagnostic tools and novel therapeutic targets for pediatric rheumatology patients.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19DADA2Pediatric

Related Articles

    ADA2 Mutation Connects Vascular Pathology to Immunodeficiency

    June 13, 2014

    Two new studies that examine the effects of a genetic defect in adenosine deaminase 2 may advance a gene-based definition of vasculopathy

    DADA2 Research Reveals Mechanisms & Possible Gene Therapy

    February 18, 2018

    SAN DIEGO—An increasing number of patients is being identified with deficiency of adenosine deaminase type 2 (DADA2); fortunately, researchers and clinicians continue to better understand the genetic disease as well, experts said in a session at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. The childhood-onset disease involves loss-of-function mutations to the CECR1 gene (i.e., cat…

    COPA Syndrome: What Do We Know About This Rare Disease?

    April 17, 2021

    ACR CONVERGENCE 2020—Tiphanie Phillips Vogel, MD, PhD, assistant professor of pediatrics and internal medicine at Baylor College of Medicine, Houston, moderated the session on COPA syndrome, which drew 324 attendees on a Sunday morning. This rare genetic cause of immune dysregulation can present like anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, lupus, lupus nephritis or rheumatoid…

    Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More

    August 31, 2021

    PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences